Abstract Library

#4665 Prognostic value of systemic inflammatory parameters in neuroendocrine tumour patients treated with peptide receptor radionuclide therapy – Preliminary results

Introduction: PRRT (177Lu-Dotatate) is a therapeutic option for advanced NETs (neuroendocrine tumours). Systemic inflammatory parameters, such as NLR, PLR, SII, and other ratios derived from complete blood counts, are considered prognostic markers in NETs and other malignancies.

Conference:

Presenting Author: Maciejewski A

Authors: Maciejewski A, Komarnicki P, Musiałkiewicz J, Gut P, Ruchała M,

Keywords: neuroendocrine tumour, PRRT, systemic inflammatory parameter, PLR, prognostic biomarker,

#4644 First results of peptide-receptor radionuclide therapy in the Russian population of patients with neuroendocrine neoplasms

Introduction: Peptide-receptor radionuclide therapy (PRRT) has demonstrated its efficacy and safety in a number of clinical trials and has become widely used in the treatment of patients with neuroendocrine neoplasms (NEN) expressing somatostatin receptors.

Conference:

Presenting Author: Baranova O

Authors: Baranova O, Geliashvili T, Markovich A, Zhulikov Y, Evdokimova E,

Keywords: NET, PRRT, 177Lu-DOTATATE,

#4618 The exceptionally rare phenomenon of well-differentiated colon neuroendocrine tumours

Introduction: Colonic neuroendocrine tumours (NETs), excluding rectal NETs, are often described as relatively common and aggressive, with inferior median survival compared to other gastrointestinal (GI) primary sites. However, epidemiological databases may conflate well-differentiated NETs with poorly differentiated NECs, leading to unclear data on prevalence, clinical behaviour, and prognosis of well-differentiated colonic NETs.

Conference:

Presenting Author: Al-Toubah T

Authors: Al-Toubah T, Strosberg J,

Keywords: colon, neuroendocrine tumour, caecum, sigmoid, neuroendocrine neoplasm,

#4599 Endosonography guided coloenterostomy for management of malignant small bowel ileus

Introduction: Small-bowel ileus (SBI) is often decisive for the prognosis in midgut neuroendocrine tumours (NET) and other peritoneally metastasised neoplasias. Conventional procedures of palliative care deliver unsatisfying results.

Conference:

Presenting Author: Weich A

Authors: Weich A, Retzbach L, Hartung V, Brand M, Kudlich T,

Keywords: Coloenterostomy, Endosonography, small bowel ileus, peritoneal carcinomatosis, midgut NET,

#4589 Clinical efficacy of RLT to assess OS and PFS using 177Lu DOTATATE, 90Y DOTATATE, and a mixture of both in patients with advanced, unresectable, progressive rectal NET – A retrospective analysis

Introduction: Retrospective, single-arm, open-label, case series study evaluating the efficacy of different types of radioligand therapy (RLT): 177Lu, 90Y DOTATATE, or mix of both used in advanced, unresectable progressive rectal NETG1/G2.

Conference:

Presenting Author: Ćwikła J

Authors: Kolasińska-Ćwikla A, Sankowski A, Pałucki J, Sekelcka N, Ćwikła J,

Keywords: Rectal Neuroendocrine Tumour, SST Receptor, Radioligand Therapy (RLT),